World No. 2 and five-time Grand Slam champion Iga Swiatek has accepted a one-month suspension after testing positive for the banned substance trimetazidine (TMZ), the International Tennis Integrity Agency said on Thursday.
Swiatek tested positive in an out-of-competition sample in August, but the ITIA, which runs tennis’ anti-doping program, accepted that it was caused by contamination of her medication melatonin, which was manufactured and sold over the counter in her native Poland.
Swiatek said she had been taking it for jet lag and sleep issues and as there was no significant fault or negligence, the ITIA ruled it was “the lowest end of the range” and offered the reigning French Open champion a one-month suspension that the 23-year-old accepted.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.